Phase II Study of Paclitaxel and Cisplatin as Second-line Chemotherapy in Advanced Non-small Cell Lung Cancer / 영남의대학술지
Yeungnam University Journal of Medicine
; : 198-206, 2004.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-121430
Responsible library:
WPRO
ABSTRACT
BACKGROUND:
To evaluate the efficacy and safety of paclitaxel and cisplatin against advanced non-small cell lung cancer (NSCLC) as a second-line chemotherapy. SUBJECTS ANDMETHODS:
Twenty-five patients were enrolled. The patients received 200 mg/m2 paclitaxel as a 3-hour intravenous infusion and 60 mg/m2 cisplatin as 30-minute intravenous infusion with vigorous hydration on day 1 every 28 days. The response was assessed every 2 cycles.RESULTS:
All 25 patients were assessed for their response and toxicity. Partial responses were observed in 5 patients. The overall response rate was 20% (95% confidence interval, 4%~36%) and the median response duration was 4.5 (range, 2-11) months. The median time to progression was 3.3 (range, 0-14) months. The median overall survival of all patients was 7.4 (range, 1.3-39) months. The hematologic toxicities were minor and easily controlled.CONCLUSION:
The combination chemotherapy of paclitaxel and cisplatin as a second-line treatment has a moderate efficacy with an acceptable toxicity in patients with advanced NSCLC.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Infusions, Intravenous
/
Cisplatin
/
Paclitaxel
/
Carcinoma, Non-Small-Cell Lung
/
Drug Therapy
/
Drug Therapy, Combination
Limits:
Humans
Language:
Korean
Journal:
Yeungnam University Journal of Medicine
Year:
2004
Document type:
Article